NCT01283724View on ClinicalTrials.gov

Visanne Study to Assess Safety in Adolescents

PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

June 30, 2014

Conditions
Endometriosis
Interventions
DRUG

Dienogest (Visanne, BAY86-5258)

Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.

Trial Locations (36)

1060

Vienna

1090

Vienna

3100

Sankt Pölten

4020

Linz

6020

Innsbruck

8010

Graz

8044

Graz

10117

Berlin

12200

Berlin

12587

Berlin

13000

Prague

13509

Berlin

14129

Berlin

14193

Berlin

20100

Turku

20357

Hamburg

23538

Lübeck

26121

Oldenburg

26655

Westerstede

36209

Vigo

37001

České Budějovice

39701

Písek

41013

Seville

41014

Seville

46017

Valencia

48149

Münster

49033

Angers

75018

Paris

76031

Rouen

91054

Erlangen

94275

Le Kremlin-Bicêtre

625 00

Brno

Unknown

Prague

02100

Espoo

00100

Helsinki

03503

Benidorm

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY